COMMUNIQUÉS West-GlobeNewswire

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
14/06/2026
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New results from the Phase [...]
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
14/06/2026
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or reduced pituitary [...]
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
14/06/2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced [...]
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
14/06/2026
Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU Seven months after the completion of dosing (Week 76), up to 64% of patients [...]
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
14/06/2026
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension – – Coordinated reductions in biomarkers of [...]
HorseWood & HorseBoost [Exclusive Report 2026] The Horse Gelatin Trick Male Enhancement Or Why Talking About Natural Vitality Supplement Horse Boost?
14/06/2026
Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male [...]
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
14/06/2026
CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseases CDX-622 targets the soluble form of stem cell factor (SCF), [...]
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
14/06/2026
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the [...]
KFSH Highlights Human-Centered AI as a Path to Better Care at HLTH Europe 2026
14/06/2026
RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe 2026 in Amsterdam, taking place from June 15 to 18, King Faisal Specialist Hospital & Research Centre (KFSH) will highlight that the value of [...]
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
14/06/2026
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent in vivo CAR-T [...]
KFSH met en avant une IA centrée sur l’humain comme la voie vers de meilleurs soins au HLTH Europe 2026
14/06/2026
RIYADH, Arabie saoudite, 14 juin 2026 (GLOBE NEWSWIRE) -- Au HLTH Europe 2026 à Amsterdam, du 15 au 18 juin, le King Faisal Specialist Hospital & Research Centre (KFSH) soulignera le fait que la valeur de l’ [...]
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
13/06/2026
Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trial COPENHAGEN, Denmark, [...]
HeroMD 4-MAX Claims Evaluated: Why Men Searching "Most Effective 4-in-1 Erectile Dysfunction Formula" Are Comparing SURGE, PRIME and The HERO System Explained
13/06/2026
Sublingual Compounded Vardenafil, Sildenafil, Tadalafil, and Apomorphine for Prescription ED Treatment: 10-Minute Onset and 36-Hour Active Window Researched Kennewick, WA, June 13, 2026 (GLOBE NEWSWIRE) -- Compounded [...]
L’EAACI appelle à une « Vision Zéro » pour un avenir libéré du fardeau des allergies et de l’asthme
13/06/2026
Réunis à Istanbul, des spécialistes de renom en allergologie exploreront les moyens par lesquels la science, la prévention et les politiques peuvent réduire l’impact mondial des maladies allergiques ZURICH, 13 juin 2026 [...]
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
13/06/2026
Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE ® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse [...]
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
13/06/2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and [...]
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
13/06/2026
Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses showed patients in mitapivat arm had clinically meaningful [...]
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
13/06/2026
Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026 HAELO manuscript simultaneously published in the New [...]
KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026
13/06/2026
RIYADH, Saudi Arabia, June 13, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will use its participation at HLTH Europe 2026, taking place from June 15 to 18 in Amsterdam, to [...]

Pages